Bomi Italia : 6-12-2017 BOMI ITALIA S.P.A. - BOMI GROUP ANNOUNCES THE BINDING COMMITMENT TO ACQUIRE DE SALUTE S.R.L.

Bomi Italia S.p.A.

- PRESS RELEASE -

Bomi Group announces a binding commitment to acquire De Salute S.r.l.

Vaprio d'Adda, 6 December 2017 - Bomi Italia S.p.A. ("Bomi" or the "Company" or the "Issuer"), the parent company of Bomi Group, a leader in the biomedical logistics sector and in the management of high technology healthcare products which is listed on the multilateral trading facility AIM Italia / Alternative Investment Market announces that, earlier today, it entered into a binding agreement (the "Agreement") to acquire the entire share capital of "De Salute S.r.l." ("De Salute"), based in Soresina (Cremona), which specialises in offering logistical and related services to the pharmaceutical industry (biotech and generics).

Founded in 1999, De Salute specialises in logistical services for biotech, pharmaceutical and hi-tech healthcare products, operating through two pharmaceutical laboratories - duly authorised to process the secondary packaging of such products, including narcotics - linked to a Good Manufacturing Practice (GMP) certified warehouse. In 2016, the company generated turnover amounting to about EUR 9.3 million with EBITDA (as defined under the IAS) of about EUR 1.2 million and an Adjusted Net Financial Position (as defined under the IAS) of about 3.1 million.

The acquisition is in line with the Bomi Group's ongoing strategy of consolidation in Europe, aimed, above all, at expanding its service offerings in a market that not only features promising value-added prospects but also enables the Group to benefit from interesting synergies in the transport services.

The acquisition entails a cash payment of about EUR 2,450,000 at closing, as well as a performance-linked earn-out component (capped at EUR 1,600,000), and is, accordingly, fully coherent with the Bomi Group's expansion and growth strategies.

In line with normal business practices, the acquisition is subject to certain conditions precedent, all of which must be met by the final deadline of 28 February 2018, including the approval of a resolution by Bomi's Board of Directors, authorising the transaction.

Giorgio Ruini, Chairman of Bomi Italia S.p.A, commented: "We are delighted to have reached this agreement with a company renowned for excellence in Italy, with values and aspirations that fully reflect those of Bomi Group. Besides boosting Bomi's expertise in the biotech and pharmaceutical sectors, this transaction is set to increase Bomi's vertical capabilities and know-how, thanks especially to De Salute's vast experience in pharmaceutical secondary repackaging. From our part, we sincerely hope that Bomi's international network could prove to be a lever for growth and for streamlining processes for all our customers

Maria Rosa Stellari, CEO of De Salute S.r.l., commented: "I am exceedingly happy that our company will soon be part of the Bomi Group, especially since this step will open new growth opportunities for De Salute. We shall continue to collaborate with our usual professionalism but with added passion, with a view to ensuring that our organisation becomes increasingly synonymous with reliability for the pharmaceutical industry."

__________________________________________________________________________________________________

. . . . . . . . . . . . . . . . . . .. . . .

 The net financial position was adjusted to reflect the restructuring of real estate assets valued at EUR 450,000.00, to be completed prior to Closing.

Bomi Italia S.p.A., is the Parent Company of Bomi Group, a world leader in the biomedical logistics sector and in the management of high technology healthcare products. It was one of the first companies to receive the "Elite" certificate issued by Borsa Italiana.

Bomi Group's activities are concentrated in the integrated logistics sector and offer a wide range of logistics services in outsourcing to companies operating in the healthcare sector, managing distribution of medical equipment, pharmaceuticals, in-vitro diagnostic equipment, reagents and implant products.

Bomi Group's portfolio of about 100 clients includes some of the world's top healthcare companies (such as the leading pharmaceutical companies and producers of healthcare devices) as well as small and medium sized companies operating at a global level in the biomedical, diagnostics and biotech industries.

Bomi Group currently has about 1,080 employees and operates through subsidiary companies and significant investments in companies in Europe, South America, China and the United States and its services are also provided through strategic alliances with local partners, in several other countries.

ISIN for Ordinary Shares: IT005108748 - Ticker for Ordinary Shares: BOMI

ISIN for Convertible Bonds: IT005114480 - Ticker for Convertible Bonds: BOMI20

For further information:

● Bomi Italia S.p.A. ●
Investor Relator	Nominated Adviser
tel: [phone]	tel: [phone]
e.mail:[e-mail]	e.mail:[e-mail]

• ● Intesa Sanpaolo S.p.A. ●